✦ LIBER ✦

CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism

✍ Scribed by Qiang Nie; Xue-ning Yang; She-juan An; Xu-chao Zhang; Jin-ji Yang; Wen-zhao Zhong; Ri-qiang Liao; Zhi-hong Chen; Jian Su; Zhi Xie; Yi-long Wu

Book ID: 116430747
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 289 KB
Volume: 47
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2011.04.018

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The epidermal growth factor receptor int

The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib

✍ Qiang Nie; Zhen Wang; Guo-chun Zhang; She-juan An; Jia-yin Lin; Ai-lin Guo; Rong 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 255 KB

OP62 Polymorphisms in AKT1 and EGFR as p

OP62 Polymorphisms in AKT1 and EGFR as possible new biomarkers of clinical outcome and toxicity in non-small-cell lung cancer patients treated with gefitinib

✍ E. Giovannetti; P. Zucali; C. Tibaldi; E. Smit; A. Falcone; A. Santoro; L. Leon; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 41 KB

The T393C polymorphism ofGNAS1as a predi

The T393C polymorphism ofGNAS1as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinum

✍ Xie, Fa-Jun; Zhao, Peng; Kou, Jun-Yan; Hong, Wei; Fu, Li; Hu, Lin; Hong, Dan; Su 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 311 KB

Phase II study of S-1 combined with oxal

Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity

✍ Kim, K-p; Jang, G; Hong, Y S; Lim, H-S; Bae, K-s; Kim, H-S; Lee, S S; Shin, J-G; 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 414 KB